Effect of a high monounsaturated vs high polyunsaturated fat hypocaloric diets in nonalcoholic fatty liver disease

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 7, 2014, Pages 1041-1047

  Aller, R ^a   De Luis, D A ^a   Izaola, O ^a   De La Fuente, B ^a   Bachiller, R ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

Author keywords

High monunsaturated fat hypocaloric diet; High polyunsaturated fat hypocaloric diet; Insulin resistance; Nonalcoholic fatty liver disease; Obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOUNSATURATED FATTY ACID; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL; EDIBLE OIL; INSULIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; INSULIN RESISTANCE; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; AGED; BLOOD; DIET THERAPY; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; ALANINE TRANSAMINASE; BODY MASS INDEX; CHOLESTEROL; DIET, REDUCING; DIETARY FATS, UNSATURATED; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; WEIGHT LOSS;

EID: 84902149840     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. LUDWIG J, VIGGIANO TR, MCGILL D.B., OH BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiencies with a hitherto unnamed disease. Mayo Clinic Proc 1980; 55: 434-438. (Pubitemid 10057164)
2. VUPPALANCHI R, CHALASANI N. NAFLD and non alcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-317.
3. CLARK JM. The epidemiology of NALFD in adults. J Clin Gastroenterol 2006; 40: s5-s10.
4. HAMAGUCHI M, KOJIMA T, OHBORN A., TAKEDA N, PUKUI M, KATO T. Protective effect of alcohol consumpotion for fatty liver but not metabolic syndrome. World j Gastroenterol 2012; 18: 156-167.
5. CHIANG DJ, PRITCHARD MT, NAGY LE Obesity, diabetes mellitus and liver fibrosis. Am J Physiol Gastrointestinal Liver Physiol 2011; 300: g697-702.
6. MARCEAU P, BIRON S, HOULD F.S., MARCEAU S., SIMARD S, THUNG SN, KRAL JG Liver pathology and the metabolic syndrome X in severe obesity. J Clin En-docrinol Metab 1999; 84: 1513-1517. (Pubitemid 30644245)
7. DRENICK WJ, SIMMON F, MURPHY JF Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med 1970; 282: 829-834.
8. ANDERSEN T, GLUUD C, FRANZMANN M.B., CHRISTOFFERSEN P. Hepatic effects of dietary weight loss in morbidity obese subjects. J Hepatol 1991; 12: 224-229.
9. ROZENTAL P, BIAVA C, SPENCER H., ZIMMERMANN HJ Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967; 12: 198-208.
10. SUZUKI A, LINDOR K, ST SAVER J, LYMP J, MENDES F., MUTO A, OKADA T, ANGULO P. Effect of changes on body weight and lifestyle in non alcoholic fatty liver disease. J Hepatol 2005; 43: 1060-1066. (Pubitemid 41627993)
11. DE LUIS D.A., ALLER R, IZAOLA O., CONDE R, GONZALEZ M, GONZÁLEZ JM. Effect of a hypocaloric diet in transaminases in nonalcoholic fatty liver disease and obese patients, relation with insulin resistance. Diab Res Clin Pract 2008; 79: 74-78.
12. DE LUIS D.A., ALLER R, IZAOLA O., GONZALEZ SAGRADO M, CONDE R. Effect of two different hypocaloric diets in transminases and insulin resistance in nonalcoholic fatty liver disease and obese patients. Nutr Hosp 2010; 25: 730-735.
13. MATHEWS DR, HOSKER J P, RUDENSKI AS, NAYLOR B.A., TREACHER D F. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-414.
14. a.
15. MATAIX J, MAÑAS M. Tablas de composición de ali-mentos españoles. Ed: University of Granada, 2003.
16. WANG Y, AUSMAN LM, RUSSELL R.M., GREENSBERG AS, WANG XD Increased apoptosis in high fat diet induced nonalcoholic steatohepatitis in rats is associated wit c-jun NH2 terminal kinase activation and elevated proapopototic Bax. J Nutr 2008; 138: 1866-1871.
17. DIABETES PREVENTION PROGRAM RESEARCH GROUP, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 6(346): 393-403.
18. CHITTURI S, ABEYGUNASEKERA S, FARRELL G., HOLMESWALKER J. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 73: 373-378.
19. MARCHESINI G, BRIZI M, MORSELLI-LABATE A, BIANCHI G., BUGIANESI E, MCCULLOUGH AJ Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-454.
20. SANYAL AJ, CAMPBELL SARGENT C, MIRSHASHI F, RIZZO W.B., CONTOS MJ, STERLING RK, LUKETIC VA. Nonalcoholic steatohepatitis: Association of insulin resistance and mitocohondrial abnormalities. Gas-troenterology 2001; 120: 1183-1192. (Pubitemid 32246672)
21. HSICH PS, HSICH YJ Impact of liver diseases on the development of type 2 diabetes mellitus. World J Gastroenterol 2011; 17: 5240-5245.
22. LICHTENSTEIN AH. Thematic review series: patient-oriented research. Dietary fat, carbohydrate, and protein: effects on plasma lipoprotein patterns. J Lipid Res 2006; 47: 1661-1667.
23. YIM JE, KIM YS, CHO M.R., CHOUSE R. Ration of fat to energy intake independently associated with the duration of diabetes and total cholesterol levels in type 2 diabetes. Nutr Res Pract 2011; 5: 157-162.
24. GHAFOORUNISSA A, IBRAHIM A, NATARAJAN S. Substituting dietary linoleic acid with alpha-linolenic acid improves insulin sensitivity in sucrose fed rats. Biochim Biophys Acta 2005; 1773: 67-75. (Pubitemid 40321172)
25. MASTERTON GS, PLEVRIS JN, HAYNES PC Review article: omega-3 fatty acids a promising novel therapy for non alcoholic fatty liver disease. Aliment Pharmacol Ther 2010; 31: 679-692.
26. THOMA C, DAY C, TRENELLI M. Lifestyle interventions for the treatment of non alcoholic fatty liver disease in adults: A systematic review. J Hepatol 2012; 56: 255-256.
27. LIEBER CS, LEO MA, MAK K.M., XU Y., CAO Q, REN C, PONOMARENKO A., DECARLI LM. Acarbose attenuates experimental non-alcoholic steatohepatitis. Biochem Biophys Res Commun 2004; 315: 699-703. (Pubitemid 38229400)
28. HARRISON SA, FINCKE C, HELSINKI D., TORGERSON S, HAYASHI P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004; 20: 623-628. (Pubitemid 39279050)
29. ZELBER-SAGI S., KESSLER A, BRAZOWSKY E., WEBB M, LURIE Y, SANTO M., LESHNO M, BLENDIS L, HALPERN Z, OREN R. A double blind randomized placebo controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 639-644.
30. SABUNCU T, NAZLIGUL Y, KARAOGLANOGLU M., UCAR E, KILIC FB THE EFFECTS OF SIBUTRAMINE AND ORLISTAT ON the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Am J Gastroenterol 2003; 12: 189-192. (Pubitemid 37152602)